BioLife Solutions Reports First Quarter 2025 Financial Results

Cell Processing revenue of $21.6 million, up 33% over Q1 2024GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66%GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenueConference call begins at 4:30 p.m. Eastern time todayBOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces ...